Old Web
English
Sign In
Acemap
>
authorDetail
>
Niki Karachaliou
Niki Karachaliou
Merck KGaA
Medicine
met amplification
Mutant
Cancer research
Pathology
3
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
2021
Journal of Thoracic Oncology
Christophe Dooms
Ernest Nadal
Jo Raskin
Ingel K. Demedts
J. Mazieres
Marie Wislez
S. Abdul
T.L. Mun
Chin-Chou Wang
Santiago Viteri
Xiuning Le
Soon Hin How
Daniel Shao-Weng Tan
Masayuki Takeda
Remi Veillon
Niki Karachaliou
Barbara Ellers-Lenz
Egbert F. Smit
Yi-Long Wu
Show All
Source
Cite
Save
Citations (0)
P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
2021
Journal of Thoracic Oncology
Chong-Kin Liam
A. Rozila Ahmad
T. Hsia
Li JunXing
Xiuning Le
John V. Heymach
J.C-H. Yang
Ross A. Soo
Ya Zhang
S-W. Kim
S. Shin
Andreas Johne
Niki Karachaliou
Rolf Bruns
B. Ellers-Lenz
Yi-Long Wu
Show All
Source
Cite
Save
Citations (0)
Novel molecular targets for the treatment of lung cancer
2019
Current Opinion in Oncology
Rafael Rosell
Niki Karachaliou
Oscar Arrieta
Show All
Source
Cite
Save
Citations (10)
1